IGM Biosciences, Inc.: restructuring charge — IGM Biosciences estimates restructuring charges of $0.7M-$2.0M from 2025 headcount reduction

IGM Biosciences, Inc.

Total restructuring charges estimated between $0.7M and $2.0M.
Cash expenditures for severance and termination: $4.1M to $5.4M, offset by non-cash stock compensation credit of $3.4M.
Substantially all charges expected to be recognized in Q1 2025.
Follows Jan 10 announcement halting imvotamab and IGM-2644 development and reducing workforce by ~73%.
Estimates subject to assumptions; actual costs may differ materially.

item 2.05

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

IGM Biosciences, Inc. announced a restructuring with charges of between $0.7 million and $2.0 million.

Type: restructuring
Charge: between $0.7 million and $2.0 million

Exact text from the filing

As a result of the 2025 Restructuring, the Company estimates it will incur total restructuring charges between $0.7 million and $2.0 million, consisting of cash expenditures between $4.1 million and $5.4 million for severance and one-time termination costs offset by non-cash compensation and stock-based compensation expense credit of $3.4 million.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0000950170-25-034626

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.